个性化医疗：肿瘤学中的基因组学试验
Personalized Medicine: Genomics Trials in Oncology.
作者信息
Hayes Daniel F, Schott Anne F
机构信息
Ann Arbor, Michigan.
出版信息
Trans Am Clin Climatol Assoc. 2015;126:133-43.
Abstract
The era of genomics-based medicine promises to provide molecular tests that will permit precision medicine. However, in 2015, it is not clear what the terms genomics-based medicine, molecular tests, or precision medicine mean. In this report, we review the definitions of these terms and other important semantics relative to what it takes to get a tumor biomarker into standard clinical practice, and the potential clinical trial designs that are being considered to determine if tumor biomarker tests based on next-generation sequencing actually provide benefit to patients with cancer.
摘要
基于基因组学的医学时代有望提供能实现精准医疗的分子检测。然而，在2015年，基于基因组学的医学、分子检测或精准医疗这些术语的含义尚不明晰。在本报告中，我们回顾了这些术语的定义以及与将肿瘤生物标志物纳入标准临床实践所需条件相关的其他重要语义，还探讨了正在考虑的潜在临床试验设计，以确定基于新一代测序的肿瘤生物标志物检测是否真的能使癌症患者获益。
相似文献
1
Personalized Medicine: Genomics Trials in Oncology.
Trans Am Clin Climatol Assoc. 2015;126:133-43.
2
Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
JAMA Oncol. 2016 Jan;2(1):13-4. doi: 10.1001/jamaoncol.2015.4503.
3
Delivering on the promise of precision cancer medicine.
Genome Med. 2016 Oct 25;8(1):110. doi: 10.1186/s13073-016-0373-1.
4
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.
5
Maurie Markman on the Groundbreaking TAPUR Trial.
Oncology (Williston Park). 2017 Mar 15;31(3):158, 168.
6
Giving Up on Precision Oncology? Not So Fast!
Clin Transl Sci. 2017 May;10(3):128-129. doi: 10.1111/cts.12457. Epub 2017 Feb 21.
7
New ESMO scale ranks mutations as cancer medicine targets.
Lancet Oncol. 2018 Oct;19(10):e513. doi: 10.1016/S1470-2045(18)30664-8. Epub 2018 Aug 31.
8
Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1179-1181. doi: 10.1080/17474124.2018.1535897. Epub 2018 Oct 17.
9
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11.
10
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
Ann Oncol. 2019 Nov 1;30(11):1691-1694. doi: 10.1093/annonc/mdz392.
引用本文的文献
1
3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine.
Phenomics. 2023 Oct 4;4(2):171-186. doi: 10.1007/s43657-023-00111-3. eCollection 2024 Apr.
2
Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes.
Int J Mol Sci. 2023 Jan 24;24(3):2288. doi: 10.3390/ijms24032288.
3
Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput.
Micromachines (Basel). 2020 Feb 18;11(2):208. doi: 10.3390/mi11020208.
4
I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment.
PLoS Comput Biol. 2019 Apr 30;15(4):e1006951. doi: 10.1371/journal.pcbi.1006951. eCollection 2019 Apr.
5
In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.
Sci Rep. 2018 Feb 13;8(1):2886. doi: 10.1038/s41598-018-21200-8.
6
Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future.
BioDrugs. 2018 Feb;32(1):53-68. doi: 10.1007/s40259-017-0258-x.
7
Clinically Meaningful Use of Blood Tumor Markers in Oncology.
Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30.
8
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.
Drug Discov Today. 2016 Sep;21(9):1399-1411. doi: 10.1016/j.drudis.2016.07.003. Epub 2016 Jul 12.
本文引用的文献
1
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.
2
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.
3
Comprehensive molecular portraits of human breast tumours.
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
4
Personalized oncology through integrative high-throughput sequencing: a pilot study.
Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.
5
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19.
6
Randomized clinical trials with biomarkers: design issues.
J Natl Cancer Inst. 2010 Feb 3;102(3):152-60. doi: 10.1093/jnci/djp477. Epub 2010 Jan 14.
7
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.
8
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
Genet Med. 2009 Jan;11(1):3-14. doi: 10.1097/GIM.0b013e318184137c.
9
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22.
10
Clinical trial designs for predictive marker validation in cancer treatment trials.
J Clin Oncol. 2005 Mar 20;23(9):2020-7. doi: 10.1200/JCO.2005.01.112.
Zotero 插件